natgillin/translations-raw huggingface dataset:
It contains two different active substances linagliptin and metformin.
Vsebuje dve različni zdravilni učinkovini, linagliptin in metformin.
A paediatric Phase 2 study examined the pharmacokinetics and pharmacodynamics of 1 mg and 5 mg linagliptin in children and adolescents ≥10 to <18 years of age with type 2 diabetes mellitus.
V pediatrični študiji faze 2 so preučevali farmakokinetiko in farmakodinamiko 1 mg in 5 mg linagliptina pri otrocih in mladostnikih s sladkorno boleznijo tipa 2, starih ≥ 10 do < 18 let.
A significantly higher incidence of malignant lymphomas only in female mice at the highest dose (> 200 times human exposure) is not considered relevant for humans (explanation: nontreatment related but due to highly variable background incidence).
Pomembno večja pojavnost malignih limfomov, ki so jo odkrili samo pri mišjih samicah pri največjih odmerkih (preko 200-krat večje kot za človeka), pa ni pomembna za ljudi (pojasnilo: pojavnost ni bila povezana z zdravljenjem, temveč z močno spremenljivo osnovno pojavnostjo).
What Jentadueto looks like and contents of the pack
Izgled zdravila Jentadueto in vsebina pakiranja
Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including patients of Caucasian, Hispanic, African, and Asian origin.
Rasa ni zaznavno vplivala na koncentracijo linagliptina v plazmi, kar je pokazala sestavljena analiza razpoložljivih farmakokinetičnih podatkov, ki je zajela bolnike bele rase ter latinskoameriškega, afriškega in azijskega izvora.
If a dose is missed, it should be taken as soon as the patient remembers.
Če bolnik pozabi vzeti odmerek, ga mora vzeti takoj, ko se spomni.
Therefore, clinically relevant interactions would not be expected with other P-glycoprotein/CYP3A4 inhibitors.
Zato niso verjetne klinično pomembne interakcije z drugimi zaviralci P-glikoproteina ali CYP3A4.
If pancreatitis is suspected, Jentadueto should be discontinued; if acute pancreatitis is confirmed, Jentadueto should not be restarted.
Pri sumu na pankreatitis je treba zdravljenje z zdravilom Jentadueto prekiniti; če je akutni pankreatitis potrjen, zdravljenja z zdravilom Jentadueto ni dovoljeno nadaljevati.
General toxicity studies in rats for up to 13 weeks were performed with the co-administration of linagliptin and metformin.
V študijah splošne toksičnosti, ki so jih do 13 tednov izvajali pri podganah, so dajali linagliptin in metformin sočasno.
• Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.
• induktorji OCT1 (npr. rifampicin) lahko poveča obseg gastrointestinalne absorpcije in učinkovitost metformina,
NAME OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim (Logo)
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Boehinger Ingelheim (logotip)
It is assumed that the pharmacokinetics of metformin hydrochloride absorption are non-linear.
Domnevajo, da je farmakokinetika absorpcije metforminijevega klorida nelinearna.
Simulations of steady-state plasma concentrations of linagliptin with and without ritonavir indicated that the increase in exposure will not be associated with an increased accumulation.
Simulacije koncentracije linagliptina v plazmi v stanju dinamičnega ravnovesja ob prisotnosti ritonavirja in brez njega so pokazale, da povečane izpostavljenosti ne spremlja povečano kopičenje.
If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma.
Če se pri vas pojavijo ti simptomi, boste morda potrebovali takojšnje bolnišnično zdravljenje, saj lahko laktacidoza vodi v komo.
500 mg Twice Daily
500 mg dvakrat na dan
- Film coating: hypromellose, titanium dioxide (E171), talc, propylene glycol.
Filmska obloga: hipromeloza, titanov dioksid (E171), smukec, propilenglikol.
Some symptoms need immediate medical attention You should stop taking Jentadueto and see your doctor straight away if you experience the following symptoms of low blood sugar (hypoglycaemia): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion.
Pri pojavu nekaterih simptomov je potrebna takojšnja zdravniška oskrba Zdravilo Jentadueto morate takoj prenehati jemati in obiskati zdravnika, če se pojavijo znaki nizkega krvnega sladkorja (hipoglikemije): tresenje, znojenje, anksioznost, meglen vid, mravljinci v ustnicah, bledica, sprememba razpoloženja ali zmedenost.
• Acute conditions with the potential to alter renal function such as: dehydration, severe infection,
• akutna stanja, pri katerih se lahko spremeni ledvično delovanje, kot so: dehidracija, huda okužba, šok
Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis.
Laktacidoza, zelo redek a resen presnovni zaplet, se najpogosteje pojavi ob akutnem poslabšanju delovanja ledvic, ob kardiorespiratorni bolezni ali sepsi.
1,000 mg Twice Daily
1000 mg dvakrat na dan
If you are not sure, talk to your doctor or pharmacist before taking this medicine.
Če ste v dvomih, se pogovorite s svojim zdravnikom ali farmacevtom, preden boste vzeli to zdravilo.
These changes in linagliptin pharmacokinetics were not considered to be clinically relevant.
Opisane spremembe farmakokinetike linagliptina niso klinično pomembne.
The study population included 2089 (35%) patients with cardiovascular disease and 1130 (19%) patients with renal impairment with an eGFR < 60ml/min/1.73m2 at baseline.
Študijska populacija je vključevala 2089 (35 %) bolnikov s srčno-žilno boleznijo in 1130 (19 %) bolnikov z ledvično okvaro, ki so imeli izhodiščni eGFR < 60 ml/min/1,73 m2.
At the recommended metformin hydrochloride doses and dosing schedules, steady-state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/ml.
Pri uporabi priporočenih odmerkov po shemah odmerjanja doseže metforminijev klorid koncentracijo v stanju dinamičnega ravnovesja v plazmi v 24 do 48 urah in je na splošno manjša od 1 μg/ml.
• Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib,
• zaviralci OCT2 (npr. cimetidin, dolutegravir, ranolazin, trimetoprim, vandetanib, izavukonazol)
Metformin hydrochloride partitions into erythrocytes.
Metforminijev klorid se porazdeli v eritrocite.
In analyses for albuminuria progression (change from normoalbuminuria to micro- or macroalbuminuria, or from microalbuminuria to macroalbuminuria) the estimated hazard ratio was 0.86 (95% CI 0.78, 0.95) for linagliptin versus placebo.
Pri analizah napredovanja albuminurije (sprememba z normoalbuminurije v mikro- ali makroalbuminurijo ali z mikroalbuminurije v makroalbuminurijo) je bilo ocenjeno razmerje tveganja 0,86 (95-% IZ 0,78; 0,95) za linagliptin v primerjavi s placebom.
As a result of tissue binding, the mean apparent volume of distribution at steady-state following a single 5 mg intravenous dose of linagliptin to healthy subjects is approximately 1110 litres, indicating that linagliptin extensively distributes to the tissues.
Zaradi tkivne vezave je srednji navidezni volumen porazdelitve v stanju dinamičnega ravnovesja po enem intravenskem odmerku 5 mg linagliptina pri zdravih prostovoljcih približno 1.110 litrov, kar kaže, da se linagliptin obsežno porazdeli v tkiva.
The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg linagliptin, is approximately 12 hours.
Efektivna razpolovna doba za kopičenje linagliptina, določena pri peroralnem dajanju večkratnih odmerkov po 5 mg, je približno 12 ur.
Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC (area under the curve) and a 35 minute prolongation of the time to peak plasma concentration were observed.
Po dajanju odmerka po 850 mg so izmerili za 40 % manjšo največjo koncentracijo v plazmi, za 25 % manjšo AUC (površino pod krivuljo) in za 35 minut podaljšan čas do največje koncentracije v plazmi.
Approximately 19% of the population had eGFR ≥45 to <60 mL/min/1.73 m2, 28% of the population had eGFR ≥30 to <45 mL/min/1.73 m2) and 15%
Približno 19 % populacije je imelo oGFR med ≥ 45 in < 60 ml/min/1,73 m2, 28 % populacije je imelo oGFR med ≥ 30 in < 45 ml/min/1,73 m oGFR pri 15 % populacije pa je znašal < 30 ml/min/1,73 m2.
Co-administration with other potent inducers of P-glycoprotein and CYP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied.
Sočasno dajanje z drugimi močnimi induktorji P-glikoproteina in CYP3A4, na primer s karbamazepinom, fenobarbitalom in fenitoinom, ni raziskano.
Hypoglycaemia may occur when Jentadueto is administered together with sulphonylurea (≥ 1 case per 10 patients).
Hipoglikemija se lahko pojavi, če jemlje bolnik zdravilo Jentadueto hkrati s sulfonilsečnino (≥ 1 primer na 10 bolnikov).
In clinical studies, as described below, linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).
V opisanih kliničnih študijah linagliptin ni klinično pomembno vplival na farmakokinetiko metformina, gliburida, simvastatina, varfarina, digoksina ali peroralnih kontraceptivov, kar je kazalec in vivo, da je možnost povzročanja interakcij zdravila s substrati CYP3A4, CYP2C9, CYP2C8, P-glikoproteina in organskih kationskih prenašalcev (organic cationic transporter - OCT) majhna.
Gastrointestinal disorders such as, nausea, vomiting, diarrhoea and decreased appetite and abdominal pain occur most frequently during initiation of therapy with Jentadueto or metformin hydrochloride and resolve spontaneously in most cases.
Bolezni prebavil, kot so navzea, bruhanje, driska in zmanjšan tek ter trebušna bolečina, se najpogosteje pojavljajo na začetku zdravljenja z zdravilom Jentadueto ali metforminijevim kloridom ter večinoma spontano minejo.
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics.
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. nesteroidna protivnetna zdravila, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia).
Ni verjetno, da bi to zdravilo samo znižalo raven krvnega sladkorja na prenizko vrednost (hipoglikemija).
The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI) or a non-fatal stroke (3P-MACE).
Namen študije je bil pokazati neinferiornost primarnega srčno-žilnega izida, sestavljenega iz prvega pojava srčno-žilne smrti ali neusodnega miokardnega infarkta (MI) ali neusodne možganske kapi (3P-MACE).
They have "D2/850" debossed on one side and the Boehringer Ingelheim logo debossed on the other.
Na eni strani imajo vtisnjeno oznako “D2/850”, na drugi pa logotip Boehringer Ingelheim.
Hypoglycaemia has not been seen with metformin hydrochloride doses of up to 85 g, although lactic acidosis has occurred in such circumstances.
Pri odmerkih metforminijevega klorida do 85 g niso zasledili hipoglikemije, se je pa pri teh odmerkih pojavila laktacidoza.
If you take more Jentadueto than you should
Če ste vzeli večji odmerek zdravila Jentadueto, kot bi smeli
They have "D2/1000" debossed on one side and the Boehringer Ingelheim logo debossed on the other.
Na eni strani imajo vtisnjeno oznako “D2/1000”, na drugi pa logotip Boehringer Ingelheim.
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.
Zdravljenje se sme ponovno uvesti najmanj 48 ur po kirurškem posegu ali začetku peroralnega prehranjevanja, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno.
Linagliptin and its main metabolite did not show a genotoxic potential.
Linagliptin in njegov glavni presnovek nista delovala genotoksično.
Stop taking Jentadueto and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Takoj prenehajte jemati zdravilo Jentadueto in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
Metformin hydrochloride is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.
Metforminijev klorid je bigvanid z antihiperglikemičnim učinkom, ki zmanjšuje osnovno in postprandialno glukozo v plazmi.
Some patients experienced rash (frequency uncommon), hives (urticaria; frequency rare), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing (angioedema; frequency rare).
Pri nekaterih bolnikih so se pojavili izpuščaj (pogostnost občasna), koprivnica (urtikarija; pogostnost redka) in otekanje obraza, ustnic, jezika in grla, kar lahko otežuje dihanje ali požiranje (angioedem; pogostnost redka).
Difference from placebo (adjusted mean) (95% CI)
Razlika v primerjavi s placebom (prilagojena srednja vrednost) (95-odstotni IZ)
If you need to have major surgery you must stop taking Jentadueto during and for some time after the procedure.
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Jentadueto.
Sulphonylureas:
Sulfonilsečnine:
D-55216 Ingelheim am Rhein, Germany.
D-55216 Ingelheim am Rhein, Nemčija.
Jentadueto has no or negligible influence on the ability to drive and use machines.
Zdravilo Jentadueto nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
* Based on lipase elevations >3xULN observed in clinical trials # Based on Linagliptin cardiovascular and renal safety study (CARMELINA), see also below Adverse reactions reported in patients who received metformin as monotherapy and that were not observed in patients receiving Jentadueto.
* Na podlagi zvišanja ravni lipaze > 3 x ULN, opaženega pri kliničnih preskušanjih Na podlagi Študije o srčno-žilni in ledvični varnosti linagliptina (CARMELINA), glejte spodaj Neželeni učinki, o katerih so poročali pri bolnikih, ki so jemali metformin kot monoterapijo, in niso bili opaženi pri bolnikih, ki so jemali zdravilo Jentadueto.
Jentadueto may cause a very rare (may affect up to 1 user in 10,000), but very serious side effect called lactic acidosis (see section ‘Warnings and precautions').
Zdravilo Jentadueto lahko povzroči zelo redek (pojavi se lahko pri do 1 od 10.000 bolnikov), a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
Linagliptin is an inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase 4) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucosedependent insulinotropic polypeptide).
Linagliptin je zaviralec DPP-4 (dipeptidil-peptidaze 4), encima, ki sodeluje pri inaktivaciji dveh inkretinskih hormonov GLP-1 in GIP (glukagonu podoben peptid 1, od glukoze odvisni insulinotropni polipeptid).
Adults with normal renal function (GFR ≥90 ml/min) The dose of antihyperglycaemic therapy with Jentadueto should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of 5 mg linagliptin plus 2,000 mg of metformin hydrochloride.
Odrasli z normalnim delovanjem ledvic (GFR ≥ 90 ml/min) Odmerek za antihiperglikemično zdravljenje z zdravilom Jentadueto je treba individualno prilagoditi bolnikovemu obstoječemu režimu zdravljenja, učinkovitosti in prenašanju, ne da bi prekoračili največji priporočeni dnevni odmerek, ki je 5 mg linagliptina in 2000 mg metforminijevega klorida.
Some patients have experienced inflammation of the pancreas (pancreatitis; frequency rare, may affect up to 1 in 1000 people).
Nekateri bolniki so imeli vnetje trebušne slinavke (pankreatitis; pogostnost redka, pojavi se lahko pri največ 1 od 1.000 bolnikov).
If you forget to take Jentadueto
Če ste pozabili vzeti zdravilo Jentadueto
Furthermore GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
GLP-1 poleg tega zmanjša izločanje glukagona iz celic alfa trebušne slinavke, kar zmanjša nastajanje glukoze v jetrih.
Hypoglycaemia is not identified as adverse reaction for linagliptin, metformin, or linagliptin plus metformin.
Hipoglikemija ni opredeljena kot neželeni učinek linagliptina, metformina ali linagliptina in metformina.
Co-administration of a high-fat meal with linagliptin prolonged the time to reach Cmax by 2 hours and lowered Cmax by 15%, but no influence on AUC 0-72h was observed.
Pri sočasnem obroku z veliko vsebnostjo maščob se je čas do dosežene Cmax podaljšal za dve uri, vrednost Cmax pa je bila za 15 % manjša, vendar vpliva na AUC0-72h niso opazili.
If you stop taking Jentadueto
Če ste prenehali jemati zdravilo Jentadueto
Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the active substance.
Plazemska koncentracija linagliptina se manjša v treh fazah in z dolgim končnim razpolovnim časom (ki za to zdravilo znaša več kot 100 ur), ki je pretežno posledica nasičene, tesne vezave linagliptina na DPP-4 in ne povečuje kopičenja zdravilne učinkovine.
Non-clinical reproduction studies did not indicate an additive teratogenic effect attributed to the coadministration of linagliptin and metformin.
Neklinične študije o razmnoževanju ne kažejo na aditivni teratogeni učinek, ki bi ga lahko pripisali sočasnemu dajanju linagliptina in metformina.
At more than 100 times human exposure, irritation of the stomach was the major finding in these monkeys.
Pri izpostavljenosti, ki je več kot 100-krat presegala določeno za človeka, je bil glavni izvid v teh opisih dražeč učinek v želodcu.
Caution is therefore advised, especially in patients with renal impairment, when these drugs are coadministered with metformin, as metformin plasma concentration may increase.
Tako je priporočena previdnost pri sočasni uporabi metformina z navedenimi zdravili, še zlasti pri bolnikih z ledvično okvaro, saj lahko pride do povečanja koncentracije metformina v plazmi.
After repeated doses of 500 mg twice daily for 7 days in paediatric patients the peak plasma concentration (Cmax) and systemic exposure (AUC0-t) were reduced by approximately 33% and 40%, respectively compared to diabetic adults who received repeated doses of 500 mg twice daily for 14 days.
Po ponovljenih odmerkih po 500 mg, ki so jih dajali dvakrat na dan 7 dni pediatričnim bolnikom, sta bili največja koncentracija v plazmi (Cmax) in sistemska izpostavljenost (AUC0-t) za približno 33 % oziroma 40 % manjši v primerjavi z vrednostmi pri odraslih bolnikih s sladkorno boleznijo, ki so prejemali ponovljene odmerke po 500 mg dvakrat na dan 14 dni.
Some patients have experienced allergic reactions (frequency rare), which may be serious, including wheezing and shortness of breath (bronchial hyperreactivity; frequency uncommon (may affect up to 1 in 100 people)).
Nekateri bolniki so imeli alergijske reakcije (pogostnost redka), ki so lahko resne, vključno s piskanjem v pljučih in zasoplostjo (bronhialna hiperreaktivnost; pogostnost občasna (pojavi se lahko pri največ 1 od 100 bolnikov)).
No metabolites have been identified in humans.
Pri ljudeh niso identificirali nobenih presnovkov.
Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
Kombinacije, pri katerih je potrebna previdnost Glukokortikoidi (pri sistemski in lokalni uporabi), agonisti beta-2 in diuretiki imajo intrinzično hiperglikemično delovanje.
Mean reductions from baseline in HbA1c were generally greater for patients with higher baseline HbA1c values.
Srednje znižanje ravni HbA1c v primerjavi z izhodiščno ravnijo je bilo večinoma večje pri bolnikih z višjo izhodiščno ravnijo HbA1c.
Absolute bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet is approximately 50-60% in healthy subjects.
Absolutna biološka uporabnost tablete po 500 mg ali 850 mg metforminijevega klorida je pri zdravih preizkušancih približno 50 do 60 %.
In addition the pharmacokinetic characteristics of linagliptin were found to be similar in dedicated phase I studies in Japanese, Chinese and Caucasian healthy subjects and African American type 2 diabetes patients.
Poleg tega so bile farmakokinetične značilnosti linagliptina podobne tudi v namenskih študijah I. faze, ki so zajele zdrave Japonce, Kitajce in belce ter Američane afriškega izvora s sladkorno boleznijo tipa 2.
Adverse reactions reported in all clinical trials with the linagliptin+metformin combination or the use of the monocomponents (linagliptin or metformin) in clinical trials or from post-marketing experience are shown below according to system organ class.
Neželeni učinki, o katerih so poročali v vseh kliničnih preskušanjih s kombinacijo linagliptina z metaforminom ali pri uporabi monokomponent (linagliptina ali metformina) v kliničnih preskušanjih oziroma na podlagi izkušenj po začetku trženja, so spodaj prikazani po organski sistemih.
Linagliptin concentrations in this study were within the range of values previously observed in younger type 2 diabetes patients.
V njej so bile koncentracije linagliptina znotraj razpona vrednosti, ki so jih prej izmerili pri mlajših bolnikih s sladkorno boleznijo tipa 2.
If you take more Jentadueto tablets than you should have, you may experience lactic acidosis.
Če ste vzeli večji odmerek zdravila Jentadueto, kot bi smeli, lahko pride do laktacidoze.
Hypoglycaemia (frequency very common (may affect more than 1 in 10 people)) is an identified side effect for the combination of Jentadueto plus sulphonylurea and for the combination Jentadueto plus insulin.
Hipoglikemija (pogostnost: zelo pogosto (pojavi se lahko pri več kot 1 od 10 bolnikov)) je znan neželeni učinek kombinacije zdravila Jentadueto in sulfonilsečnine ter kombinacije zdravila Jentadueto in insulina.
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/l to 75-89% at ≥ 30 nmol/l, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin At high concentrations, where DPP-4 is fully saturated, 70-80% of linagliptin was bound to other plasma proteins than DPP-4, hence 20-30% were unbound in plasma.
Vezava linagliptina na beljakovine v plazmi je odvisna od koncentracije in se zmanjša od približno 99 % pri 1 nmol/l na 75 do 89 % pri ≥ 30 nmol/l, kar priča o zasičenosti vezave na DPP-4 pri večanju koncentracije linagliptina.Pri velikih koncentracijah, pri katerih je DPP-4 povsem zasičen, se je 70 do 80 % linagliptina vezalo še na druge beljakovine v plazmi poleg DPP-4, zato ga je bilo 20 do 30 % nevezanega v plazmi.
The incidence of hypoglycaemia was similar across treatment groups (placebo 1.4%, linagliptin 5 mg 0%, metformin 2.1%, and linagliptin 2.5 mg plus metformin twice daily 1.4%).
Pojavnost hipoglikemije je bila v skupinah podobna (placebo 1,4 %, linagliptin 5 mg 0 %, metformin 2,1 % in linagliptin 2,5 mg + metformin dvakrat na dan 1,4 %).
Incretins are secreted at a low basal level throughout the day and levels rise immediately after meal intake.
Inkretini se v majhni količini izločajo ves dan, tik po jedi pa se njihova raven zviša.